Sökning: AMNE:(MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Endokrinologi och diabetes) > The Combination of ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08528naa a2201057 4500 | |
001 | oai:DiVA.org:his-23666 | |
003 | SwePub | |
008 | 240321s2024 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/336181 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-236662 URI |
024 | 7 | a https://doi.org/10.3390/cells130504142 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/3361812 URI |
040 | a (SwePub)hisd (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Tejedor, Sandrau Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden,Translationell bioinformatik, Translational Bioinformatics4 aut0 (Swepub:his)tejs |
245 | 1 0 | a The Combination of Vascular Endothelial Growth Factor A (VEGF-A) and Fibroblast Growth Factor 1 (FGF1) Modified mRNA Improves Wound Healing in Diabetic Mice :b An Ex Vivo and In Vivo Investigation |
264 | 1 | b MDPI,c 2024 |
338 | a electronic2 rdacarrier | |
500 | a CC BY 4.0 DEED© 2024 by the authors.Correspondence Address: S. Tejedor; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 50, Sweden; email: sandra.tejedorgascon1@astrazeneca.com; K. Hansson; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 50, Sweden; email: kenny.m.hansson@astrazeneca.comThis research was partially funded by grants from the Swedish Knowledge Foundation, grant number 20200014. | |
520 | a Background: Diabetic foot ulcers (DFU) pose a significant health risk in diabetic patients, with insufficient revascularization during wound healing being the primary cause. This study aimed to assess microvessel sprouting and wound healing capabilities using vascular endothelial growth factor (VEGF-A) and a modified fibroblast growth factor (FGF1). Methods: An ex vivo aortic ring rodent model and an in vivo wound healing model in diabetic mice were employed to evaluate the microvessel sprouting and wound healing capabilities of VEGF-A and a modified FGF1 both as monotherapies and in combination. Results: The combination of VEGF-A and FGF1 demonstrated increased vascular sprouting in the ex vivo mouse aortic ring model, and topical administration of a combination of VEGF-A and FGF1 mRNAs formulated in lipid nanoparticles (LNPs) in mouse skin wounds promoted faster wound closure and increased neovascularization seven days post-surgical wound creation. RNA-sequencing analysis of skin samples at day three post-wound creation revealed a strong transcriptional response of the wound healing process, with the combined treatment showing significant enrichment of genes linked to skin growth. Conclusion: f-LNPs encapsulating VEGF-A and FGF1 mRNAs present a promising approach to improving the scarring process in DFU. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
650 | 7 | a LANTBRUKSVETENSKAPERx Veterinärmedicinx Klinisk vetenskap0 (SwePub)403032 hsv//swe |
650 | 7 | a AGRICULTURAL SCIENCESx Veterinary Sciencex Clinical Science0 (SwePub)403032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Cell- och molekylärbiologi0 (SwePub)301082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Cell and Molecular Biology0 (SwePub)301082 hsv//eng |
653 | a angiogenesis | |
653 | a diabetes | |
653 | a diabetic foot ulcer | |
653 | a FGF1 | |
653 | a revascularization | |
653 | a VEGF-A | |
653 | a wound healing | |
653 | a Animals | |
653 | a Diabetes Mellitus | |
653 | a Experimental | |
653 | a Diabetic Foot | |
653 | a Disease Models | |
653 | a Animal | |
653 | a Fibroblast Growth Factor 1 | |
653 | a Humans | |
653 | a Mice | |
653 | a Neovascularization | |
653 | a Physiologic | |
653 | a Vascular Endothelial Growth Factor A | |
653 | a vasculotropin A | |
653 | a animal | |
653 | a disease model | |
653 | a experimental diabetes mellitus | |
653 | a human | |
653 | a metabolism | |
653 | a mouse | |
653 | a physiology | |
653 | a Bioinformatik | |
653 | a Bioinformatics | |
653 | a diabetes | |
653 | a diabetic foot ulcer | |
653 | a angiogenesis | |
653 | a revascularization | |
653 | a VEGF-A | |
653 | a FGF1 | |
653 | a wound healing | |
700 | 1 | a Wågberg, Mariau Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Correia, Cláudiau Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Åvall, Karinu Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Hölttä, Mikkou Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Hultin, Leifu Imaging and Data Analytics, Clinical and Pharmacological Safety Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Lerche, Michaelu Advanced Drug Delivery, Pharmaceutical Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Davies, Nigelu Advanced Drug Delivery, Pharmaceutical Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Bergenhem, Nilsu Alliance Management, Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, United States4 aut |
700 | 1 | a Snijder, Arjanu Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Marlow, Tomu Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Dönnes, Pierreu Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,SciCross AB, Skövde, Sweden,Translationell bioinformatik, Translational Bioinformatics4 aut0 (Swepub:his)donp |
700 | 1 | a Fritsche-Danielson, Reginau Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Synnergren, Janeu Gothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Translationell bioinformatik ,Translational Bioinformatics,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xsynja |
700 | 1 | a Jennbacken, Karinu Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
700 | 1 | a Hansson, Kennyu Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden4 aut |
710 | 2 | a Högskolan i Skövdeb Institutionen för biovetenskap4 org |
773 | 0 | t Cellsd : MDPIg 13:5q 13:5x 2073-4409 |
856 | 4 | u https://doi.org/10.3390/cells13050414y Fulltext |
856 | 4 | u https://his.diva-portal.org/smash/get/diva2:1846121/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-23666 |
856 | 4 8 | u https://doi.org/10.3390/cells13050414 |
856 | 4 8 | u https://gup.ub.gu.se/publication/336181 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.